Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study
In the era of immune checkpoint inhibitors, understanding the metastatic microenvironment of proficient mismatch repair/microsatellite stable (pMMR/MSS) colorectal cancer (CRC) is of paramount importance to both prognostication and the development of more effective novel therapies. In this study, pr...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13173 |
| _version_ | 1828728988370993152 |
|---|---|
| author | Marine Jary Wen‐Wei Liu Dongyao Yan Isaac Bai Andrea Muranyi Elise Colle Isabelle Brocheriou Anthony Turpin Nina Radosevic‐Robin Pierre Bourgoin Frédérique Penault‐Llorca Romain Cohen Dewi Vernerey Thierry André Christophe Borg Kandavel Shanmugam Magali Svrcek |
| author_facet | Marine Jary Wen‐Wei Liu Dongyao Yan Isaac Bai Andrea Muranyi Elise Colle Isabelle Brocheriou Anthony Turpin Nina Radosevic‐Robin Pierre Bourgoin Frédérique Penault‐Llorca Romain Cohen Dewi Vernerey Thierry André Christophe Borg Kandavel Shanmugam Magali Svrcek |
| author_sort | Marine Jary |
| collection | DOAJ |
| description | In the era of immune checkpoint inhibitors, understanding the metastatic microenvironment of proficient mismatch repair/microsatellite stable (pMMR/MSS) colorectal cancer (CRC) is of paramount importance to both prognostication and the development of more effective novel therapies. In this study, primary and paired metastasis tissue samples were collected from patients with resectable metastatic CRC treated with adjuvant FOLFOX or peri‐operative chemotherapy in the MIROX phase III prospective study. In total, 74 cancer tissues were stained for CD3, CD8, Forkhead box protein 3 (FOXP3), programmed cell death protein‐1 (PD‐1, invasive front, stromal, intra‐epithelial compartments), and programmed death‐ligand 1 (PD‐L1, tumor, immune cells). The immune profiling of primary CRC had a limited value to predict the immune context of paired metastases for all markers but CD3+. The expression of CD8 and PD‐L1 was higher in metastases after neoadjuvant FOLFOX. In metastases, both CD3 T cells at the invasive front and PD‐L1 expressions on immune cells were predictive of better disease‐free survival. These results show that the effect of FOLFOX on modifying the immune microenvironment in resected CRC metastases and measurement of PD‐L1 expression and tumor‐infiltrating CD8 T cells in pMMR/MSS metastatic tissue samples could improve treatment strategies of metastatic CRC patients. |
| first_indexed | 2024-04-12T14:25:08Z |
| format | Article |
| id | doaj.art-528753a036b940b0a01d68a276c317a4 |
| institution | Directory Open Access Journal |
| issn | 1574-7891 1878-0261 |
| language | English |
| last_indexed | 2024-04-12T14:25:08Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj.art-528753a036b940b0a01d68a276c317a42022-12-22T03:29:28ZengWileyMolecular Oncology1574-78911878-02612022-06-0116112260227310.1002/1878-0261.13173Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort studyMarine Jary0Wen‐Wei Liu1Dongyao Yan2Isaac Bai3Andrea Muranyi4Elise Colle5Isabelle Brocheriou6Anthony Turpin7Nina Radosevic‐Robin8Pierre Bourgoin9Frédérique Penault‐Llorca10Romain Cohen11Dewi Vernerey12Thierry André13Christophe Borg14Kandavel Shanmugam15Magali Svrcek16Multidisciplinary Group in Oncology (GERCOR) Paris FranceVentana Medical Systems Inc. Tucson AZ USAVentana Medical Systems Inc. Tucson AZ USAVentana Medical Systems Inc. Tucson AZ USAVentana Medical Systems Inc. Tucson AZ USADepartment of Medical Oncology University Hospital of Beaujon Clichy FranceDepartment of Pathology Assistance Publique‐Hôpitaux de Paris Pitié‐Salpêtrière Hospital Sorbonne University Paris FranceMultidisciplinary Group in Oncology (GERCOR) Paris FranceDepartment of Pathology, Centre Jean Perrin Clermont‐Ferrand FranceDepartment of Pathology Assistance Publique‐Hôpitaux de Paris Saint‐Antoine Hospital Sorbonne University Paris FranceDepartment of Pathology, Centre Jean Perrin Clermont‐Ferrand FranceMultidisciplinary Group in Oncology (GERCOR) Paris FranceMultidisciplinary Group in Oncology (GERCOR) Paris FranceMultidisciplinary Group in Oncology (GERCOR) Paris FranceMultidisciplinary Group in Oncology (GERCOR) Paris FranceVentana Medical Systems Inc. Tucson AZ USAMultidisciplinary Group in Oncology (GERCOR) Paris FranceIn the era of immune checkpoint inhibitors, understanding the metastatic microenvironment of proficient mismatch repair/microsatellite stable (pMMR/MSS) colorectal cancer (CRC) is of paramount importance to both prognostication and the development of more effective novel therapies. In this study, primary and paired metastasis tissue samples were collected from patients with resectable metastatic CRC treated with adjuvant FOLFOX or peri‐operative chemotherapy in the MIROX phase III prospective study. In total, 74 cancer tissues were stained for CD3, CD8, Forkhead box protein 3 (FOXP3), programmed cell death protein‐1 (PD‐1, invasive front, stromal, intra‐epithelial compartments), and programmed death‐ligand 1 (PD‐L1, tumor, immune cells). The immune profiling of primary CRC had a limited value to predict the immune context of paired metastases for all markers but CD3+. The expression of CD8 and PD‐L1 was higher in metastases after neoadjuvant FOLFOX. In metastases, both CD3 T cells at the invasive front and PD‐L1 expressions on immune cells were predictive of better disease‐free survival. These results show that the effect of FOLFOX on modifying the immune microenvironment in resected CRC metastases and measurement of PD‐L1 expression and tumor‐infiltrating CD8 T cells in pMMR/MSS metastatic tissue samples could improve treatment strategies of metastatic CRC patients.https://doi.org/10.1002/1878-0261.13173immune profileoligometastatic colorectal cancerPD‐L1pMMRT lymphocytes |
| spellingShingle | Marine Jary Wen‐Wei Liu Dongyao Yan Isaac Bai Andrea Muranyi Elise Colle Isabelle Brocheriou Anthony Turpin Nina Radosevic‐Robin Pierre Bourgoin Frédérique Penault‐Llorca Romain Cohen Dewi Vernerey Thierry André Christophe Borg Kandavel Shanmugam Magali Svrcek Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study Molecular Oncology immune profile oligometastatic colorectal cancer PD‐L1 pMMR T lymphocytes |
| title | Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study |
| title_full | Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study |
| title_fullStr | Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study |
| title_full_unstemmed | Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study |
| title_short | Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study |
| title_sort | immune microenvironment in patients with mismatch repair proficient oligometastatic colorectal cancer exposed to chemotherapy the randomized mirox gercor cohort study |
| topic | immune profile oligometastatic colorectal cancer PD‐L1 pMMR T lymphocytes |
| url | https://doi.org/10.1002/1878-0261.13173 |
| work_keys_str_mv | AT marinejary immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT wenweiliu immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT dongyaoyan immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT isaacbai immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT andreamuranyi immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT elisecolle immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT isabellebrocheriou immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT anthonyturpin immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT ninaradosevicrobin immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT pierrebourgoin immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT frederiquepenaultllorca immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT romaincohen immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT dewivernerey immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT thierryandre immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT christopheborg immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT kandavelshanmugam immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy AT magalisvrcek immunemicroenvironmentinpatientswithmismatchrepairproficientoligometastaticcolorectalcancerexposedtochemotherapytherandomizedmiroxgercorcohortstudy |